PT - JOURNAL ARTICLE AU - Assawakosri, Suvichada AU - Kanokudom, Sitthichai AU - Suntronwong, Nungruthai AU - Auphimai, Chompoonut AU - Nilyanimit, Pornjarim AU - Vichaiwattana, Preeyaporn AU - Thongmee, Thanunrat AU - Duangchinda, Thaneeya AU - Chantima, Warangkana AU - Pakchotanon, Pattarakul AU - Srimuan, Donchida AU - Thatsanatorn, Thaksaporn AU - Klinfueng, Sirapa AU - Yorsang, Ritthideach AU - Sudhinaraset, Natthinee AU - Wanlapakorn, Nasamon AU - Mongkolsapaya, Juthathip AU - Honsawek, Sittisak AU - Poovorawan, Yong TI - Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination AID - 10.1101/2022.01.28.22269986 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.28.22269986 4099 - http://medrxiv.org/content/early/2022/01/29/2022.01.28.22269986.short 4100 - http://medrxiv.org/content/early/2022/01/29/2022.01.28.22269986.full AB - Background The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve the protection against the delta and omicron variants.Methods A total of 224 individuals who completed the two-dose CoronaVac for six months were included. We studied reactogenicity and immunogenicity following a heterologous booster with the inactivated vaccine (BBIBP), the viral vector vaccine (AZD1222), and the mRNA vaccine (both BNT162B2 and mRNA-1273). We also determined immunogenicity at 3- and 6-months boosting intervals.Results The solicited adverse events (AEs) were mild to moderate and well-tolerated. Total RBD immunoglobulin (Ig), anti-RBD IgG, focus reduction neutralization test (FRNT50) against delta and omicron variants, and T cell response were highest in the mRNA-1273 group followed by the BNT162b2, AZD1222 and BBIBP groups, respectively. We also witnessed a higher total Ig anti-RBD in the long-interval than in the short-interval groups.Conclusions All four booster vaccines significantly increased binding and NAbs in individuals immunized with two doses of CoronaVac. The present evidence may benefit vaccine strategies development to thwart variants of concern, including the omicron variant.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Clinical Trials Registry (TCTR 20210910002)Funding StatementThis work was supported by the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital and was partially supported by the Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported by National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613 to T.D.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB numbers 546/64) and was performed according to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines (ICH-GCP). Informed consent was obtained prior to participant enrolment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript